

Innovate to Elevate Pancreatic Cancer Care

Immunity leading the way in precision medicine

1. The strategic modulation of anti-tumor immunity is paramount in improving outcomes for patients with resected pancreatic cancer (*this thesis*)
2. Considering sex disparities in clinical decision-making is essential for optimizing therapeutic outcomes (*this thesis*)
3. Models combining multiple circulating biomarkers are optimal for accurate prediction of (non-)response to a single cycle of FOLFIRINOX chemotherapy (*this thesis*)
4. FOLFIRINOX triggers various facets of a potent anti-tumor immune response, opening avenues for enhanced efficacy by integrating immunotherapy (*this thesis*)
5. Rintatolimod boosts anti-tumor immunity in advanced pancreatic cancer, with immune checkpoint inhibition heightening its therapeutic efficacy (*this thesis*)
6. A detailed understanding of roadblocks in anti-tumor immunity in pancreatic cancer is urgently needed to develop effective therapeutic strategies (*S. Yousuf, Gastroenterology, 2023*)
7. Analysis of the pancreatic tumor immune and stromal microenvironment is challenging because of the numerous heterogeneous layers (interpatient, inpatient, and intratumoral) (*M. Hilmi, Lancet, 2024*)
8. Adaptive clinical trial designs incorporating parallel drug evaluation platforms and multi-omics biomarkers for patient stratification are necessary to facilitate a precision medicine strategy for pancreatic cancer (*G. O'Kane, Journal of Clinical Oncology, 2022*)
9. A goal without a plan is just a wish (*Antoine de Saint-Exupéry, 1944*)
10. Research is what I'm doing when I don't know what I'm doing (*Wernher von Braun, 1973*)
11. I definitely feel there's room for improvement (*Roger Federer, 2003*)